Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Monsenso ASOCSE:MONSO -7.38%27 EV-to-EBITDA is -6.85 as of Aug. 04, 2026. GuruFocus rates OCSE:MONSO with a GF Score™ of 27/100 and a GF Value™ of kr0.15 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 508 Healthcare Providers & Services companies, Monsenso AS ranks worse than 196850.2% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Monsenso AS's enterprise value is kr20.22 Mil.
Monsenso AS's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was kr-2.95 Mil. Therefore, Monsenso AS's EV-to-EBITDA for today is -6.85.
The historical rank and industry rank for Monsenso AS's EV-to-EBITDA or its related term are showing as below:
OCSE:MONSO'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -64.75 Med: -4.68 Max: 943.48
Current: -6.85
During the past 9 years, the highest EV-to-EBITDA of Monsenso AS was 943.48. The lowest was -64.75. And the median was -4.68.
OCSE:MONSO's EV-to-EBITDA is ranked worse than 100% of 508
companies
in the Healthcare Providers & Services industry
Industry Median: 11.02
vs OCSE:MONSO: -6.85
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Monsenso AS's PE Ratio (TTM) for today is calculated as:
Monsenso AS's share price for today is kr0.276.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Monsenso AS's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was kr-0.110.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Monsenso AS's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OCSE:MONSO vs VEEV, BTSG, HQY: EV-to-EBITDA Comparison
For the Health Information Services subindustry, Monsenso AS's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Monsenso AS EV-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Monsenso AS's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Monsenso AS's EV-to-EBITDA falls into.
Monsenso AS's current Enterprise Value is kr20.22 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Monsenso AS's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was kr-2.95 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Monsenso AS (OCSE:MONSO) has a EV-to-EBITDA of -6.85 as of Aug. 04, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Monsenso AS. According to the industry distribution chart, Monsenso AS ranks #999999 out of 508 companies in the Healthcare Providers & Services industry.
Is Monsenso AS's EV-to-EBITDA too high?
Monsenso AS's current EV-to-EBITDA is -6.85. Based on the distribution chart, Monsenso AS ranks #999999 out of 508 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Monsenso AS has a GF Score™ of 27/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Monsenso AS's EV-to-EBITDA compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Monsenso AS ranks #999999 out of 508 companies for EV-to-EBITDA. This places Monsenso AS in the lower half of its industry. The industry median EV-to-EBITDA is 11.02. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Healthcare Providers & Services company?
The median EV-to-EBITDA among Healthcare Providers & Services companies is 11.02, based on 508 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Monsenso AS. For the Healthcare Providers & Services industry, the median EV-to-EBITDA is 11.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Monsenso AS's current EV-to-EBITDA is -6.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Monsenso AS stock overvalued right now?
Based on GuruFocus' analysis, Monsenso AS (OCSE:MONSO) is currently considered Significantly Overvalued. The stock's GF Value™ is kr0.15, compared to a current price of kr0.28 — trading 84% above its estimated fair value. The current EV-to-EBITDA is -6.85. Monsenso AS's overall GF Score™ is 27/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Monsenso AS (OCSE:MONSO), the current EV-to-EBITDA is -6.85 as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Monsenso AS (OCSE:MONSO) Overvalued in 2026?
Based on GuruFocus' analysis, Monsenso AS stock appears to be overvalued.
The current stock price of kr0.28 is trading 84% above its estimated GF Value™ of kr0.15.
GuruFocus considers Monsenso AS to be Significantly Overvalued.
Key valuation signals for OCSE:MONSO:
EV-to-EBITDA: -6.85
GF Value™: kr0.15 vs. price of kr0.28 (84% above fair value)
No single metric tells the full story. See the OCSE:MONSO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Monsenso AS is a mobile mental health company. It technology company offering a digital health solution used for decentralized trials, remote patient monitoring, and treatment support. The company's mission is to contribute to improved health for more people at lower costs by supporting treatment digitally and leveraging patient-reported outcomes data, and the solution helps optimise the treatment and gives a detailed overview of an individual's health through the collection of outcome, adherence, and behavioral data.
27GF Score
Get the complete analysis for OCSE:MONSO
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OCSE:MONSO has been successfully added to your 
